85610-72-6

Basic information

• Product Name: 3,3-diphenyl-N-[(2R)-1-phenylpropan-2-yl]propan-1-amine
• Synonyms: Benzenepropanamine, N-((1R)-1-methyl-2-phenylethyl)-gamma-phenyl-
• CAS NO: 85610-72-6
• Molecular Formula: C₂₄H₂₇N
• Molecular Weight: 329.4779
• Mol File: 85610-72-6.mol
• Article Data: 8

Chemical Properties

• Boiling Point: 476.1°C at 760 mmHg
• Flash Point: 219.4°C
• Density: 1.023g/cm³
• Vapor Pressure: 3.14E-09mmHg at 25°C
• Refractive Index: 1.577
• CAS DataBase Reference: 3,3-diphenyl-N-[(2R)-1-phenylpropan-2-yl]propan-1-amine(CAS DataBase Reference)
• NIST Chemistry Reference: 3,3-diphenyl-N-[(2R)-1-phenylpropan-2-yl]propan-1-amine(85610-72-6)
• EPA Substance Registry System: 3,3-diphenyl-N-[(2R)-1-phenylpropan-2-yl]propan-1-amine(85610-72-6)

Safety Data

• Hazardous Substances Data: 85610-72-6(Hazardous Substances Data)

Upstream product

• 2327-99-3 1-phenylpropadiene 
• 5586-73-2 3-diphenylpropyl amine 
• 2286-54-6 3,3-diphenyl-propionitrile 
• 60-15-1 2-amino-1-phenylpropane 
• 29648-95-1 1-chloro-3,3-diphenylpropane 

Downstream Products

• 20017-70-3 2-Diethylamino-N-(3,3-diphenyl-propyl)-N-(1-methyl-2-phenyl-ethyl)-acetamide 

Relevant articles and documents

A New N-Trityl-Substituted Aminopyridinato Titanium Catalyst for Hydroamination and Hydroaminoalkylation Reactions - Unexpected Intramolecular C-H Bond Activation

Sterically demanding 2,6-bis(tritylamino)pyridine is used for the synthesis of a mono(2,6-diaminopyridinato) titanium complex that undergoes unexpected intramolecular C-H bond activation to give access to an unusual 1-titanaisoindoline derivative. Both titanium complexes do not show high catalytic activity for hydroaminoalkylation reactions of alkenes but exceptional results are obtained in the field of alkene, alkyne, and allene hydroamination including room temperature activity for intramolecular alkene hydroamination, excellent regioselectivity of intermolecular alkyne and allene hydroamination as well as selectivity for hydroamination over hydroaminoalkylation during cyclization reactions of primary aminoalkenes.

ANTIHYPERTENSIVE THERAPY

A new use of darusentan is provided in preparation of a pharmaceutical composition for lowering blood pressure in a patient exhibiting resistance to a baseline antihypertensive therapy with one or more drugs. The composition comprises darusentan in an amount providing a therapeutically effective daily dose; wherein (a) the composition is orally deliverable and/or (b) the daily dose of darusentan is effective to provide a reduction of at least about 3 mmHg in one or more blood pressure parameters selected from trough sitting systolic, trough sitting diastolic, 24-hour ambulatory systolic, 24-hour ambulatory diastolic, maximum diurnal systolic and maximum diurnal diastolic blood pressures. Further provided is a new use of darusentan in preparation of a pharmaceutical composition for lowering blood pressure in a patient exhibiting resistance to a baseline antihypertensive therapy, wherein the composition is administered adjunctively with at least one diuretic and at least one antihypertensive drug selected from ACE inhibitors, angiotensin II receptor blockers, beta-adrenergic receptor blockers and calcium channel blockers.

Synthesis and biological activity of allosteric modulators of GABA B receptors, Part 1. N-(Phenylpropyl)-1-arylethylamines

A series of 15 analogues of fendiline, and 34 derivatives of N-(3-phenylpropyl)-1-arylethylamine have been prepared for evaluation as positive allosteric modulators of GABAB receptors. The most active (EC50, 10 nM) was N-(3,3-diphenylpropyl)-1-(3-chloro-4-methoxyphenyl) ethylamine 6g. CSIRO 2006.